Reduced creatine kinase is a promising biomarker.

SIRT2 inhibition emerges as a promising therapeutic strategy.

Statistical significance not achieved on primary endpoint.

Autophagy increases but is impaired, leading to an increase of the HD protein in the cytosol.

Neither CoQ10 nor minocycline were helpful in the R6/2 mouse and high doses of minocycline resulted in decreased survival time.

ACR16 improves voluntary and involuntary movement. This is wonderful news!

Siena Biotech announces a safety and tolerability study with healthy volunteers, preparatory to trials in HD patients.

Normal synaptic activity is neuroprotective, that extrasynaptic activity is toxic, and that memantine will suppress the later while leaving the former unaffected.

Here is an opportunity to tell the medical professionals about quality of life issues.

A trial of mesenchymal stem cell is planned for the end of 2010.